Abstract |
Clinical experience with Ixoten ( trofosfamide), a derivative of cyclophosphamide, is reported in 29 patients with malignant lymphomas. Daily doses of 150-300 mg p.o. and 6.000-200.000 mg total dose respectively, resulted in an 80% complete or partial remission. In addition to a dose dependent haematotoxicity, other side effects (gastrointestinal and/or hair loss) were almost negligible.
|
Authors | P Pötzi, P Aiginger, J Kühböck |
Journal | Acta medica Austriaca
(Acta Med Austriaca)
Vol. 6
Issue 5
Pg. 247-9
( 1979)
ISSN: 0303-8173 [Print] Austria |
Vernacular Title | Ixoten-Therapie bei malignen Lymphomen. |
PMID | 400215
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
- Cyclophosphamide
- trofosfamide
|
Topics |
- Adult
- Aged
- Cyclophosphamide
(analogs & derivatives, therapeutic use)
- Dose-Response Relationship, Drug
- Female
- Hodgkin Disease
(drug therapy)
- Humans
- Leukemia, Lymphoid
(drug therapy)
- Lymphoma
(drug therapy)
- Lymphoma, Follicular
(drug therapy)
- Lymphoma, Non-Hodgkin
(drug therapy)
- Male
- Middle Aged
- Plasmacytoma
(drug therapy)
|